|
業務類別
|
Diagnostics & Research |
|
業務概覽
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services. |
| 公司地址
| 8000 Marina Boulevard, Brisbane, CA, USA, 94005 |
| 電話號碼
| +1 415 287-2300 |
| 傳真號碼
| +1 415 287-2456 |
| 公司網頁
| https://www.caredx.com |
| 員工數量
| 765 |
| Ms. Jessica Meng |
Chief Commercial Officer |
美元 485.41K |
27/04/2026 |
| Mr. Jeff Novack |
General Counsel and Secretary |
美元 361.92K |
27/04/2026 |
| Mr. Keith Kennedy |
Chief Operating Officer, Chief accounting officer and Chief financial officer |
美元 587.61K |
24/02/2026 |
| Mr. John Walter Hanna, Jr |
Director, President and Chief Executive Officer |
美元 693.27K |
27/04/2026 |
|
|
| Dr. Hannah A. Valantine, M.D. |
Independent Director |
27/04/2026 |
| Mr. Arthur A. Torres |
Independent Director |
27/04/2026 |
| Dr. Peter Maag, PhD |
Independent Director |
27/04/2026 |
| Mr. Michael D. Goldberg |
Chairman of the Board |
27/04/2026 |
| Mr. George W. Bickerstaff, III |
Independent Director |
27/04/2026 |
| Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D. |
Independent Director |
27/04/2026 |
| Ms. Christine M. Cournoyer |
Independent Director |
27/04/2026 |
| Mr. R. Bryan Riggsbee |
Independent Director |
27/04/2026 |
| Mr. Suresh Gunasekaran |
Independent Director |
27/04/2026 |
| Mr. John Walter Hanna, Jr |
Director, President and Chief Executive Officer |
27/04/2026 |
|
|
|
|
